1. Singas, E., Karpel, J.P.: Profile of ciclesonide for the maintenance treatment of asthma. Ther. Clin. Risk Manag. 7, 351–358 (2011). doi: 10.2147/TCRM.S5433
2. Fanta, C.H.: Asthma. N. Engl. J. Med. 360, 1002–1014 (2009). doi: 10.1056/NEJMra0804579
3. INFARMED, I.P.: Resumo das Características do Medicamento—Alvesco 160 microgramas/dose, Solução pressurizada para inalação. http://www.infarmed.pt/infomed/detalhes.php?med_id=44299&dci=&nome_comer=YWx2ZXNjbw==&dosagem=&forma_farmac=&atc=&estado_aim=&pesquisa_titular=&pagina=1 (2012). Accessed 13 March 2012
4. Food and Drugs Administration: Ciclesonide Omnaris. http://www.fda.gov/downloads/AdvisoryCommittees/CommitteesMeetingMaterials/PediatricAdvisoryCommittee/UCM166822.pdf (2012). Accessed 2 Feb 2012
5. Food and Drugs Administration: Ciclesonide: Clinical Pharmacology Review. http://www.fda.gov/downloads/Drugs/DevelopmentApprovalProcess/DevelopmentResources/ucm071869.pdf (2012). Accessed 20 Feb 2012